Search

Displaying results 8401 - 8410 of 8515 in total
  1. Drug

    Siagoside

    go.drugbank.com/drugs/DB12351
    Investigational

    Siagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease.

  2. Drug

    Human interferon omega-1

    go.drugbank.com/drugs/DB05472
    Investigational

    It has been investigated both in single and combination treatment. The biological activities of IFN-omega 1 and its physiological role are not known to date.

  3. Drug

    VX-702

    go.drugbank.com/drugs/DB05470
    Investigational

    It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.

  4. Drug

    Celivarone

    go.drugbank.com/drugs/DB16012
    Investigational

    Celivarone is under investigation in clinical trial NCT00233441 (Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 Mg OD With Amiodarone as

  5. Drug

    RO7300490

    go.drugbank.com/drugs/DB17535
    Investigational

    RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in

  6. Drug

    FB-825

    go.drugbank.com/drugs/DB17598
    Investigational

    It is currently being investigated for immune disorders, such as atopic dermatitis and hyperimmunoglobulin E syndrome (HIES).[A258448,L45743]

  7. Drug

    UDP-alpha-D-glucuronic acid

    go.drugbank.com/drugs/DB03041
    Experimental

    A nucleoside diphosphate sugar which serves as a source of glucuronic acid for polysaccharide biosynthesis.

  8. Drug

    Lumicitabine

    go.drugbank.com/drugs/DB14808
    Investigational

    Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and

  9. Drug

    COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection

    go.drugbank.com/drugs/DB15845
    Experimental

    As of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for the COVID-19 AP TP Vaccine for ‘proof of concept.’

  10. Drug

    SF1126

    go.drugbank.com/drugs/DB05210
    Investigational

    SF1126 is an integrin-targeted PI3 kinase inhibitor.